AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20542888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative high-dose remifentanil (0.25 microg kg(‐1) min(‐1))
Number of subjects: 50
Study 20542888 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative low-dose remifentanil (0.1 microg kg(‐1) min(‐1))
Number of subjects: 50
Study 18959453 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning through music (n = 20)
Number of subjects: 38
Study 18959453 — intervention group
Group type: COMPARATOR
Intervention: Learning through speech (n = 18)
Number of subjects: 38
Study 16846327 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based stress-management intervention
Number of subjects: 1085
Study 16846327 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1085
Study 14598189 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise at individual anaerobic threshold for 30 minutes
Number of subjects: 18
Study 10945120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual help group participation
Number of subjects: 0
Study 10945120 — intervention group
Group type: COMPARATOR
Intervention: Substance abuse education classes
Number of subjects: 0
Study 8629387 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Transarterial Chemoembolization (TAE)
Number of subjects: 23
Study 8629387 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 23
Study 8479126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein formula
Number of subjects: 24
Study 8479126 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 24
Study 3511931 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 19
Study 3511931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24681899 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Dysregulation (ED)
Number of subjects: 180
Study 27706948 — intervention group
Group type: EXPERIMENTAL
Intervention: UMPNL
Number of subjects: 73
Study 27706948 — intervention group
Group type: COMPARATOR
Intervention: RIRS
Number of subjects: 73
Study 24259189 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 831
Study 24259189 — intervention group
Group type: COMPARATOR
Intervention: Control (uncircumcised men)
Number of subjects: 831
Study 24259189 — intervention group
Group type: EXPERIMENTAL
Intervention: As-treated analysis (circumcised men)
Number of subjects: 831
Study 24259189 — intervention group
Group type: COMPARATOR
Intervention: As-treated analysis (uncircumcised men)
Number of subjects: 831
Study 23860366 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy at 67 µg/kg/day for 1 year
Number of subjects: 110
Study 23860366 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IGF-I levels
Number of subjects: 110
Study 23860366 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I responses after 1 year
Number of subjects: 110
Study 21170205 — intervention group
Group type: EXPERIMENTAL
Intervention: Withania somnifera (500mg/day)
Number of subjects: 40
Study 21170205 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia arjuna (500mg/day)
Number of subjects: 40
Study 21170205 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Withania somnifera and Terminalia arjuna (500mg/day each)
Number of subjects: 40
Study 21170205 — intervention group
Group type: COMPARATOR
Intervention: Placebo (capsules filled with flour)
Number of subjects: 40
Study 17684475 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs (nucleoside reverse transcriptase inhibitors)
Number of subjects: 250
Study 17684475 — intervention group
Group type: EXPERIMENTAL
Intervention: MTND1*LHON4216C
Number of subjects: 250
Study 17684475 — intervention group
Group type: EXPERIMENTAL
Intervention: MTND2*LHON4917G
Number of subjects: 250
Study 17684475 — intervention group
Group type: EXPERIMENTAL
Intervention: MTND1*LHON4216C after adjusting for confounders
Number of subjects: 250
Study 17684475 — intervention group
Group type: EXPERIMENTAL
Intervention: MTND2*LHON4917G after adjusting for confounders
Number of subjects: 250
Study 17684475 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluding 4917G individuals from analysis
Number of subjects: 250
Study 16648247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose melatonin administration in the morning
Number of subjects: 0
Study 16648247 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose melatonin administration in the afternoon/evening
Number of subjects: 0
Study 16648247 — intervention group
Group type: COMPARATOR
Intervention: Bright light exposure (treatment of choice)
Number of subjects: 0
Study 12819162 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm weaning strategy (n = 37)
Number of subjects: 68
Study 12819162 — intervention group
Group type: COMPARATOR
Intervention: Current best practice control group (n = 31)
Number of subjects: 68
Study 11128877 — intervention group
Group type: EXPERIMENTAL
Intervention: Toluene exposure (measured by urinary excretion of unmodified toluene)
Number of subjects: 49
Study 11128877 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Confusion Index
Number of subjects: 49
Study 11128877 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Confusion Index
Number of subjects: 49
Study 11128877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative toluene exposure (estimated as product of urinary excretion and previous exposure duration)
Number of subjects: 49
Study 11128877 — intervention group
Group type: COMPARATOR
Intervention: Occupational exposure limit proposed by the American Conference of Governmental Industrial Hygienists
Number of subjects: 49
Study 8799521 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg day‐1 for 1 week)
Number of subjects: 12
Study 8799521 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 12
Study 1365692 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative chemotherapy
Number of subjects: 77
Study 1365692 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 77
Study 6404595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg)
Number of subjects: 0
Study 6404595 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 0
Study 6404595 — intervention group
Group type: COMPARATOR
Intervention: Injectable placebo
Number of subjects: 0
Study 31612147 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis spray (3%) applied to cover the entire wound surface during dressing changes from week 0 until cicatrization or a maximum of 8 weeks.
Number of subjects: 31
Study 31612147 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis spray (3%)
Number of subjects: 31
Study 31612147 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 31
Study 29443664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen (12 mg, intrathecal administration on days 1, 29, 85, and 274)
Number of subjects: 126
Study 29443664 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 126
Study 29443664 — intervention group
Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 126
Study 27908454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg intramuscular injection (days 0, 14, 28, then every 28 days thereafter)
Number of subjects: 524
Study 27908454 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg orally daily
Number of subjects: 524
Study 27908454 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 524
Study 27908454 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 524
Study 24911175 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to female virtual stimuli (voice and image)
Number of subjects: 0
Study 24911175 — intervention group
Group type: COMPARATOR
Intervention: Exposure to male virtual stimuli (voice and image)
Number of subjects: 0
Study 22422103 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy alone
Number of subjects: 0
Study 22422103 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0
Study 22422103 — intervention group
Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy
Number of subjects: 0
Study 22422103 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 22422103 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy added to chemotherapy
Number of subjects: 0
Study 22422103 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 20404381 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Number of subjects: 3190
Study 20404381 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 3190
Study 18321834 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 dog visits
Number of subjects: 30
Study 18321834 — intervention group
Group type: COMPARATOR
Intervention: 12 human visits
Number of subjects: 30
Study 18321834 — intervention group
Group type: COMPARATOR
Intervention: 12 quiet reading sessions
Number of subjects: 30
Study 15772570 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d combined with MPA 2.5 mg/d (n = 20)
Number of subjects: 80
Study 15772570 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d combined with MPA 5 mg/d (n = 20)
Number of subjects: 80
Study 15772570 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed CEE 0.625 mg/d (n = 20)
Number of subjects: 80
Study 15772570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 80
Study 11819000 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning for 3 hours
Number of subjects: 12
Study 11819000 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning for 3 hours
Number of subjects: 12
Study 10406359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 2 g daily
Number of subjects: 459
Study 10406359 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine 600 mg daily
Number of subjects: 459
Study 7776521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injections of fentanyl 10‐13 micrograms.kg‐1 during lower abdominal surgery under light general anesthesia (halothane 0.3‐0.5% plus nitrous oxide and oxygen)
Number of subjects: 4
Study 7776521 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural anesthesia (intermittent injections of 1.0% lidocaine) during lower abdominal surgery under light general anesthesia
Number of subjects: 4
Study 7776521 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural anesthesia (intermittent injections of 1.0% lidocaine) during upper abdominal surgery under light general anesthesia
Number of subjects: 4
Study 7776521 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (halothane 1.0‐1.5% plus nitrous oxide and oxygen) during lower abdominal surgery
Number of subjects: 4
Study 2222129 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of short half-life benzodiazepines
Number of subjects: 57
Study 2222129 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of long half-life benzodiazepines
Number of subjects: 57
Study 2222129 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued benzodiazepine use (n = 10)
Number of subjects: 57
Study 2222129 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 47)
Number of subjects: 57
Study 2222129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients remaining free of benzodiazepines for at least 5 weeks
Number of subjects: 57
Study 1093758 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drugs
Number of subjects: 86
Study 1093758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 31209866 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest algorithm
Number of subjects: 5050
Study 27766711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor conditioning stimulus (CPCS) at 4 °C
Number of subjects: 20
Study 27766711 — intervention group
Group type: COMPARATOR
Intervention: Control session with water at 32 °C
Number of subjects: 20
Study 27766711 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor conditioning stimulus (CPCS) and Control session
Number of subjects: 20
Study 26605240 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine plus atypical antipsychotic
Number of subjects: 64
Study 26605240 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus atypical antipsychotic
Number of subjects: 64
Study 23143294 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of pediatric brain tumors
Number of subjects: 78
Study 23143294 — intervention group
Group type: COMPARATOR
Intervention: Population-based controls
Number of subjects: 78
Study 21132025 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week outpatient physical exercise program (PE), incorporating aerobic and strength exercises.
Number of subjects: 131
Study 21132025 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 131
Study 18752540 — intervention group
Group type: EXPERIMENTAL
Intervention: WoundCare 18+ (Manuka honey)
Number of subjects: 108
Study 18752540 — intervention group
Group type: COMPARATOR
Intervention: IntraSite Gel (hydrogel)
Number of subjects: 108
Study 16863588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 16863588 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (Control)
Number of subjects: 0
Study 12624570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention to lower saturated fat and cholesterol intake
Number of subjects: 0
Study 12624570 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11069572 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - beclomethasone dipropionate 200 microg or budesonide 200 microg, prescribed twice daily
Number of subjects: 86
Study 11069572 — intervention group
Group type: COMPARATOR
Intervention: Control group - beta2-agonist only
Number of subjects: 86
Study 11069572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined health care costs in the ICS group
Number of subjects: 86
Study 9235813 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam-beta-cyclodextrin 20 mg daily for 14 days
Number of subjects: 32
Study 9235813 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg daily for 14 days
Number of subjects: 32
Study 1441691 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release gallopamil, 100 mg b.i.d.
Number of subjects: 24
Study 1441691 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release nifedipine, 20 mg b.i.d.
Number of subjects: 24
Study 1441691 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 3896014 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 48
Study 3896014 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 48
Study 3896014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 48
Study 31115611 — intervention group
Group type: EXPERIMENTAL
Intervention: POP repair with mesh
Number of subjects: 255
Study 29570019 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-DW (sodium perborate-distilled water mixture)
Number of subjects: 125
Study 29570019 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-HP (sodium perborate-3% hydrogen peroxide mixture)
Number of subjects: 125
Study 29570019 — intervention group
Group type: EXPERIMENTAL
Intervention: CP (37% carbamide peroxide gel)
Number of subjects: 125
Study 29570019 — intervention group
Group type: EXPERIMENTAL
Intervention: HP (35% H2O2 gel)
Number of subjects: 125
Study 29570019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching agent)
Number of subjects: 125
Study 26522140 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative misoprostol (400μg, given rectally)
Number of subjects: 348
Study 26522140 — intervention group
Group type: COMPARATOR
Intervention: Postoperative misoprostol (400μg, given rectally)
Number of subjects: 348
Study 26522140 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (preoperative and postoperative misoprostol)
Number of subjects: 348
Study 24732494 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on the Raven robot
Number of subjects: 30
Study 24732494 — intervention group
Group type: COMPARATOR
Intervention: Training on the da Vinci robot
Number of subjects: 30
Study 22874536 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) - 12 weeks, 3 sets, 10 exercises, 3 times per week, 8-12 repetition maximum (RM)
Number of subjects: 23
Study 22874536 — intervention group
Group type: COMPARATOR
Intervention: Social Interaction (SI) - stretching, knitting, health lectures, 2 times per week (Control Group)
Number of subjects: 23
Study 22874536 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 23
Study 22874536 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Resistance Exercise (RE) bout
Number of subjects: 23
Study 22874536 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 23
Study 20143387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual direction k space traversal with maintained diffusion-encoding gradient strength and direction
Number of subjects: 0
Study 20143387 — intervention group
Group type: EXPERIMENTAL
Intervention: Distortion correction routine applied to SE-EPI fMRI acquisitions
Number of subjects: 0
Study 18661839 — intervention group
Group type: EXPERIMENTAL
Intervention: gengnianningshentang
Number of subjects: 108
Study 18661839 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 108
Study 15701463 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive pacemaker stress echocardiography (PASE)
Number of subjects: 26
Study 11858475 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously
Number of subjects: 44
Study 11858475 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously
Number of subjects: 44
Study 11858475 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy, delivered women, N = 19)
Number of subjects: 44
Study 10074877 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (maximum dose of 300 mg/day)
Number of subjects: 42
Study 10074877 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (maximum dose of 600 mg/day)
Number of subjects: 42
Study 10074877 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 42
Study 10074877 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 42
Study 10074877 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine and Chlorpromazine
Number of subjects: 42
Study 7493417 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory gasp
Number of subjects: 0
Study 2024753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 1.5% with 1/200,000 adrenaline (group L)
Number of subjects: 20
Study 2024753 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 1.5% plain (group P)
Number of subjects: 20
Study 7215756 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin (7,500 i.u. subcutaneous twice daily)
Number of subjects: 0
Study 7215756 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-synthetic heparin analogue (5,000 U subcutaneous twice daily)
Number of subjects: 0
Study 7215756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 0
Study 30591535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) lung cancer screening
Number of subjects: 680
Study 30591535 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume doubling time (VDT) and volume assessment
Number of subjects: 680
Study 30591535 — intervention group
Group type: EXPERIMENTAL
Intervention: VDT ≤590 days or volume ≥200 mm3
Number of subjects: 680
Study 25581063 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 0
Study 23821379 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal psychosocial rehabilitation intervention (three supportive talks and a residential rehabilitation course)
Number of subjects: 42
Study 23821379 — intervention group
Group type: COMPARATOR
Intervention: Usual services (control group)
Number of subjects: 42
Study 21653307 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling (2 sessions)
Number of subjects: 457
Study 21653307 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling (5 sessions)
Number of subjects: 457
Study 21653307 — intervention group
Group type: COMPARATOR
Intervention: Riskier group (standard counseling)
Number of subjects: 457
Study 21653307 — intervention group
Group type: EXPERIMENTAL
Intervention: Riskier group (enhanced counseling)
Number of subjects: 457
Study 19775999 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy after breast-conserving surgery (BCS)
Number of subjects: 42000
Study 19775999 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy after complete mastectomy
Number of subjects: 42000
Study 19775999 — intervention group
Group type: COMPARATOR
Intervention: Breast conservative surgery without radiation therapy
Number of subjects: 42000
Study 16054822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass
Number of subjects: 0
Study 16054822 — intervention group
Group type: COMPARATOR
Intervention: No cardiopulmonary bypass
Number of subjects: 0
Study 12185328 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy (PMRT)
Number of subjects: 0
Study 11072419 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 14
Study 11072419 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 14
Study 11072419 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg (placebo)
Number of subjects: 14
Study 7793647 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (150 mg)
Number of subjects: 60
Study 7793647 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (150 mg)
Number of subjects: 60